02325.HK
Yunkang Group Limited
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 0.51
−3.77%Year over year
Reported trailing growth
- Revenue
- -15.5%
- EBITDA
- +114.9%
- EBIT
- +104.4%
- EPS
- +100.0%
- Free cash flow
- -100.0%
- Operating cash flow
- -100.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -45.7%
- EBITDA
- -40.1%
- EBIT
- -58.4%
- Net income
- -80.2%
- EPS
- -80.4%
- Free cash flow
- -4.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025